ATE355836T1 - Inhibitoren der mucin-synthese - Google Patents

Inhibitoren der mucin-synthese

Info

Publication number
ATE355836T1
ATE355836T1 AT01906804T AT01906804T ATE355836T1 AT E355836 T1 ATE355836 T1 AT E355836T1 AT 01906804 T AT01906804 T AT 01906804T AT 01906804 T AT01906804 T AT 01906804T AT E355836 T1 ATE355836 T1 AT E355836T1
Authority
AT
Austria
Prior art keywords
inhibitors
mucin synthesis
mucin
synthesis
Prior art date
Application number
AT01906804T
Other languages
English (en)
Inventor
Yuhong Zhou
Roy C Levitt
Nicholas C Nicolaides
Steve Jones
Mike Mclane
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of ATE355836T1 publication Critical patent/ATE355836T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT01906804T 2000-01-31 2001-01-31 Inhibitoren der mucin-synthese ATE355836T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17912700P 2000-01-31 2000-01-31
US19311100P 2000-03-30 2000-03-30
US23078300P 2000-09-07 2000-09-07
US24213400P 2000-10-23 2000-10-23
US25205200P 2000-11-20 2000-11-20

Publications (1)

Publication Number Publication Date
ATE355836T1 true ATE355836T1 (de) 2007-03-15

Family

ID=27539006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01906804T ATE355836T1 (de) 2000-01-31 2001-01-31 Inhibitoren der mucin-synthese

Country Status (13)

Country Link
US (2) US6737427B2 (de)
EP (1) EP1255544B1 (de)
JP (1) JP2004507444A (de)
AR (1) AR042578A1 (de)
AT (1) ATE355836T1 (de)
AU (2) AU2001234671B2 (de)
CA (1) CA2398642A1 (de)
CY (1) CY1106643T1 (de)
DE (1) DE60127098T2 (de)
DK (1) DK1255544T3 (de)
ES (1) ES2282235T3 (de)
PT (1) PT1255544E (de)
WO (1) WO2001054685A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345051B2 (en) * 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
AU2001234671B2 (en) * 2000-01-31 2006-05-18 Genaera Corporation Mucin synthesis inhibitors
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors
US6679264B1 (en) 2000-03-04 2004-01-20 Emphasys Medical, Inc. Methods and devices for use in performing pulmonary procedures
US8474460B2 (en) 2000-03-04 2013-07-02 Pulmonx Corporation Implanted bronchial isolation devices and methods
US20030070683A1 (en) 2000-03-04 2003-04-17 Deem Mark E. Methods and devices for use in performing pulmonary procedures
US20030059434A1 (en) * 2000-08-09 2003-03-27 Andrew Grupe Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions
US7011094B2 (en) 2001-03-02 2006-03-14 Emphasys Medical, Inc. Bronchial flow control devices and methods of use
US20030050648A1 (en) 2001-09-11 2003-03-13 Spiration, Inc. Removable lung reduction devices, systems, and methods
CA2458595C (en) 2001-10-11 2007-12-04 Peter M. Wilson Bronchial flow control devices and methods of use
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
US6929637B2 (en) 2002-02-21 2005-08-16 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
AU2003220124A1 (en) 2002-03-08 2003-09-22 Emphasys Medical, Inc. Methods and devices for inducing collapse in lung regions fed by collateral pathways
US20030181922A1 (en) 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
US20030216769A1 (en) 2002-05-17 2003-11-20 Dillard David H. Removable anchored lung volume reduction devices and methods
US20040059263A1 (en) 2002-09-24 2004-03-25 Spiration, Inc. Device and method for measuring the diameter of an air passageway
CA2487405A1 (en) 2002-07-26 2004-02-05 Emphasys Medical, Inc. Bronchial flow control devices with membrane seal
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7100616B2 (en) 2003-04-08 2006-09-05 Spiration, Inc. Bronchoscopic lung volume reduction method
EP1644018A2 (de) 2003-05-28 2006-04-12 Wyeth Lösliche clca-1 und antagonisten von clca-1
EP1633734A2 (de) * 2003-06-19 2006-03-15 Genaera Corporation Mucin-synthesehemmer
US7533671B2 (en) 2003-08-08 2009-05-19 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
EP1773405A4 (de) * 2004-07-22 2011-10-05 Duska Scient Co Verfahren zur diagnose, überwachung und behandlung von lungenerkrankungen
US7771472B2 (en) 2004-11-19 2010-08-10 Pulmonx Corporation Bronchial flow control devices and methods of use
EP1827479A1 (de) * 2004-12-09 2007-09-05 Ingenium Pharmaceuticals AG Verfahren und mittel zur behandlung von erkrankungen, die durch überproduktion/hypersekretion von schleim verursacht werden
WO2006075172A2 (en) * 2005-01-13 2006-07-20 University Of Dundee Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
US8876791B2 (en) 2005-02-25 2014-11-04 Pulmonx Corporation Collateral pathway treatment using agent entrained by aspiration flow current
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US8940683B2 (en) 2006-08-10 2015-01-27 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2008112141A1 (en) * 2007-03-07 2008-09-18 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
EP2641572B1 (de) 2007-10-12 2019-07-24 Spiration Inc. Ventilladeverfahren, -system und -vorrichtung
GB0905954D0 (en) * 2009-04-06 2009-05-20 E Therapeutics Plc Treatment of exacerbations of asthma
US9782454B2 (en) * 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2012134965A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases
WO2013044267A1 (en) 2011-09-23 2013-03-28 Pulmonx, Inc. Implant loading device and system
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
WO2015182565A1 (ja) * 2014-05-27 2015-12-03 リンク・ジェノミクス株式会社 肺疾患治療剤
EP3186242B1 (de) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitoren von alpha-amino-beta-carboxymuconsäure semialdehyd-decarboxylase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168313A (en) 1978-02-21 1979-09-18 Sebastian Bago Phthalidyl 2-(3'-trifluoromethyl-anilino)-pyridine-3-carboxylate and its salts
US4515980A (en) * 1983-07-11 1985-05-07 Sterling Drug Inc. Substituted aminobenzoates, their preparation and use
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4666716A (en) * 1984-09-04 1987-05-19 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
DE3682136D1 (de) * 1985-07-31 1991-11-28 Hoechst Ag N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
DE3608726A1 (de) 1986-03-15 1987-09-17 Hoechst Ag Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen
GB9200114D0 (en) 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
WO1996039419A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Colon specific genes and proteins
DE29680627U1 (de) * 1995-07-20 1999-06-02 Juergens, Uwe R., Dr.med., 53859 Niederkassel Nicht-steroidales Antiphlogistikum zur topischen und systemischen Behandlung der akuten und chronischen polypoiden Rhinosinusitis
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
FI991568L (fi) * 1997-01-08 1999-07-08 Upjohn Co Farmaseuttisesti aktiivisia trisyklisiä amiineja
WO1998037881A1 (en) * 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
JP2002509536A (ja) * 1997-07-01 2002-03-26 ワーナー−ランバート・カンパニー ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用
AU2674399A (en) * 1998-02-11 1999-08-30 Regents Of The University Of California, The Compositions and methods for the inhibition of muc-5 mucin gene expression
JP2002505095A (ja) 1998-03-03 2002-02-19 マガイニン ファーマシューティカルズ インコーポレイテッド 喘息及び関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
DE69924641D1 (de) * 1999-01-07 2005-05-12 Warner Lambert Company Llc Mor Behandlung von asthma anhand von mek-inhibitoren
GEP20032999B (en) * 1999-01-13 2003-06-25 Warner Lambert Co 1-Heterocycle Substituted Diarylamines
AU2201500A (en) * 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001022935A1 (en) * 1999-09-27 2001-04-05 Oh Jun Suk Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same
AU2001234671B2 (en) 2000-01-31 2006-05-18 Genaera Corporation Mucin synthesis inhibitors
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
EP1255544A1 (de) 2002-11-13
AU3467101A (en) 2001-08-07
CY1106643T1 (el) 2012-01-25
EP1255544B1 (de) 2007-03-07
DK1255544T3 (da) 2007-09-17
AR042578A1 (es) 2005-06-29
DE60127098T2 (de) 2007-11-29
US7504409B2 (en) 2009-03-17
AU2001234671B2 (en) 2006-05-18
US6737427B2 (en) 2004-05-18
DE60127098D1 (de) 2007-04-19
JP2004507444A (ja) 2004-03-11
ES2282235T3 (es) 2007-10-16
US20040254096A1 (en) 2004-12-16
US20010041685A1 (en) 2001-11-15
WO2001054685A1 (en) 2001-08-02
EP1255544A4 (de) 2005-02-02
PT1255544E (pt) 2007-06-15
CA2398642A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
DE60127098D1 (de) Inhibitoren der mucin-synthese
NO20020287L (no) Prodroge av en ICE-inhibitor
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
EE200200403A (et) Pregabaliini asümmeetriline süntees
AR028567A1 (es) Nuevos derivados de fenil-propargileter
ATE524441T1 (de) Vla-4-inhibitoren
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
EP1496894A4 (de) Angiogenese-hemmer
AR028596A1 (es) Nuevos derivados de fenilglicina
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
ID30187A (id) Dongkrak jenis pantagraf
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
DE50113294D1 (de) Hochselektive inhibitoren des urokinase-plasminogenaktivators
FI20000510A0 (fi) Taajuusmuuttaja
DE60040535D1 (de) Schätzung der reinen verzögerung
PT1339695E (pt) Inibidores da farnesiltransferase
PT1322592E (pt) Derivados substituidos de 1-aminobutan-3-ol
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
AR028070A1 (es) Sintesis de compuestos de ciclohexendimetanol o ciclohexandimetanol
EE200200389A (et) Imidasooli uued derivaadid
PT1272470E (pt) Forma modificada da torasemida amorfa
NO20030421D0 (no) Inhibitorer av Cdc25 fosfataser
EP1222308A4 (de) Inhibitoren der antiprotozoalen histonazyltransferase
DE60132468D1 (de) Alen-lanosterol zyklase inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1255544

Country of ref document: EP

REN Ceased due to non-payment of the annual fee